Year |
Citation |
Score |
2013 |
Kaelin W, Livingston D, Loda M, Vousden K, Mihich E. Twenty-fifth annual Pezcoller Symposium: Metabolism and tumorigenesis. Cancer Research. 73: 6124-7. PMID 24097824 DOI: 10.1158/0008-5472.Can-13-2445 |
0.313 |
|
2013 |
Marais R, Sellers W, Livingston D, Mihich E. Twenty-fourth annual Pezcoller symposium: Molecular basis for resistance to targeted agents. Cancer Research. 73: 1046-9. PMID 23222297 DOI: 10.1158/0008-5472.Can-12-3236 |
0.341 |
|
2012 |
Friedl P, Hubbell J, Livingston D, Mihich E. Twenty-third annual Pezcoller Symposium: engineering influences in cancer research. Cancer Research. 72: 841-4. PMID 22237623 DOI: 10.1158/0008-5472.Can-11-3080 |
0.371 |
|
2011 |
Zaenker KS, Mihich E, Liu E. Personalized Cancer Medicine 2011: Toward Individualized Cancer Treatments. XV International Fritz Bender Symposium Held on February 21 to 23, 2011 at Matrix, Biopolis, Singapore. Translational Oncology. 4: 199-202. PMID 21804914 DOI: 10.1593/Tlo.11142 |
0.317 |
|
2006 |
Weinberg R, Mihich E. Eighteenth annual pezcoller symposium: tumor microenvironment and heterotypic interactions. Cancer Research. 66: 11550-3. PMID 17158190 DOI: 10.1158/0008-5472.Can-06-3149 |
0.307 |
|
2006 |
Gerhauser C, Bartsch H, Crowell J, De Flora S, D'Incalci M, Dittrich C, Frank N, Mihich E, Steffen C, Tortora G, Gescher A. Development of novel cancer chemopreventive agents in Europe--neglected Cinderella or rising phoenix? A critical commentary. ESF Workshop on Cancer Chemoprevention, DKFZ, Heidelberg, September 18-20, 2005. European Journal of Cancer (Oxford, England : 1990). 42: 1338-43. PMID 16730975 DOI: 10.1016/J.Ejca.2006.02.007 |
0.307 |
|
2006 |
Ewens A, Luo L, Berleth E, Alderfer J, Wollman R, Hafeez BB, Kanter P, Mihich E, Ehrke MJ. Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Research. 66: 5419-26. PMID 16707470 DOI: 10.1158/0008-5472.Can-05-3963 |
0.376 |
|
2004 |
Mihich E, Jaenisch R. Sixteenth Annual Pezcoller Symposium: stem cells and epigenesis in cancer. Cancer Research. 64: 8474-7. PMID 15548721 DOI: 10.1158/0008-5472.Can-04-2625 |
0.334 |
|
2004 |
Mihich E, Kaelin W. Fifteenth annual Pezcoller symposium: molecular in vivo visualization of cancer cells. Cancer Research. 64: 2929-33. PMID 15087414 DOI: 10.1158/0008-5472.Can-03-2995 |
0.325 |
|
2003 |
Mihich E. Cellular immunity for cancer chemoimmunotherapy--an overview. Cancer Immunology, Immunotherapy : Cii. 52: 661-2. PMID 12942199 DOI: 10.1007/S00262-003-0423-6 |
0.328 |
|
2003 |
Ujhazy P, Zaleskis G, Mihich E, Ehrke MJ, Berleth ES. Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells. Cancer Immunology, Immunotherapy : Cii. 52: 463-72. PMID 12698271 DOI: 10.1007/S00262-003-0391-X |
0.333 |
|
2001 |
Berleth ES, Masso-Welch PA, Kazim LA, Ip MM, Mihich E, Ehrke MJ. Expression, tissue distribution, and cellular localization of the antiapoptotic TIP-B1 protein. Journal of Leukocyte Biology. 69: 995-1005. PMID 11404387 DOI: 10.1189/Jlb.69.6.995 |
0.319 |
|
2001 |
Mihich E, Berleth E, Henn A, Ehrke M. Modulation of tumor necrosis factor (TNFα) in cancer therapeutics European Journal of Cancer. 37: S148. DOI: 10.1016/S0959-8049(01)81037-6 |
0.336 |
|
2000 |
Mihich E. On The Immunomodulating Effects of Anti-Cancer Drugs and Their Therapeutic Exploitation Japanese Journal of Clinical Oncology. 30: 469-471. PMID 11155915 DOI: 10.1093/Jjco/Hyd127 |
0.308 |
|
2000 |
Mihich E, Ehrke MJ. Anticancer drugs plus cytokines: immunodulation based therapies of mouse tumors. International Journal of Immunopharmacology. 22: 1077-81. PMID 11137614 DOI: 10.1016/S0192-0561(00)00072-2 |
0.348 |
|
2000 |
Ehrke MJ, Verstovsek S, Maccubbin DL, Ujházy P, Zaleskis G, Berleth E, Mihich E. Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice. International Journal of Cancer. 87: 101-9. PMID 10861459 DOI: 10.1002/1097-0215(20000701)87:1<101::Aid-Ijc15>3.0.Co;2-B |
0.333 |
|
1998 |
Ehrke MJ, Verstovsek S, Pocchiari SK, Krawczyk CM, Ujházy P, Zaleskis G, Maccubbin DL, Meer JM, Mihich E. Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation. International Journal of Cancer. 76: 579-86. PMID 9590137 DOI: 10.1002/(Sici)1097-0215(19980518)76:4<579::Aid-Ijc22>3.0.Co;2-1 |
0.347 |
|
1998 |
Ehrke MJ, Verstovsek S, Ujházy P, Meer JM, Eppolito C, Maccubbin DL, Mihich E. Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunology, Immunotherapy : Cii. 45: 287-98. PMID 9490198 DOI: 10.1007/S002620050445 |
0.343 |
|
1996 |
Ujházy P, Berleth ES, Pietkiewicz JM, Kitano H, Skaar JR, Ehrke MJ, Mihich E. Evidence for the involvement of ecto-5'-nucleotidase (CD73) in drug resistance. International Journal of Cancer. 68: 493-500. PMID 8945621 DOI: 10.1002/(Sici)1097-0215(19961115)68:4<493::Aid-Ijc15>3.0.Co;2-6 |
0.301 |
|
1996 |
Ehrke MJ, Verstovsek S, Zaleskis G, Ho RL, Ujházy P, Maccubbin DL, Mihich E. Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunology, Immunotherapy : Cii. 42: 221-30. PMID 8665569 DOI: 10.1007/S002620050274 |
0.318 |
|
1995 |
Ehrke MJ, Verstovsek S, Krawczyk CM, Ujházy P, Zaleskis G, Maccubbin DL, Mihich E. Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. International Journal of Cancer. 63: 463-71. PMID 7591249 DOI: 10.1002/Ijc.2910630327 |
0.33 |
|
1994 |
Tzai TS, Huben RP, Zaleskis G, Berleth ES, Ehrke MJ, Mihich E. Effect of perioperative chemoimmunotherapy with cyclophosphamide and autologous tumor vaccine in murine MBT-2 bladder cancer. The Journal of Urology. 151: 1680-6. PMID 8189597 DOI: 10.1016/S0022-5347(17)35344-2 |
0.367 |
|
1993 |
Verstovsek S, Maccubbin DL, Ehrke MJ, Mihich E. Polymyxin B-mediated lysis of tumor cells. International Archives of Allergy and Immunology. 100: 47-52. PMID 8428163 DOI: 10.1159/000236386 |
0.342 |
|
1988 |
Maccubbin DL, Whitman JA, Taniguchi N, Mace KF, Ehrke MJ, Mihich E. Comparison of adriamycin induced immunomodulation with that of the noncardiotoxic anthracycline 5-iminodaunorubicin. International Journal of Immunopharmacology. 10: 317-23. PMID 3263335 DOI: 10.1016/0192-0561(88)90064-1 |
0.359 |
|
1986 |
Ryoyama K, Ryoyama C, Mihich E. Inhibition of suppressor cell generation by mouse serum in culture International Journal of Immunopharmacology. 8: 23-32. PMID 2937749 DOI: 10.1016/0192-0561(86)90069-X |
0.343 |
|
1985 |
Mihich E. Biological response modifiers: their potential and limitations in cancer therapeutics. Cancer Investigation. 3: 71-83. PMID 2578860 DOI: 10.3109/07357908509040609 |
0.323 |
|
1985 |
Jane Ehrke M, Mihich E. Effects of anticancer agents on immune responses Trends in Pharmacological Sciences. 6: 412-417. DOI: 10.1016/0165-6147(85)90193-2 |
0.327 |
|
1984 |
Ryoyama K, Ehrke MJ, Mihich E. Induction of suppressor T cells in culture--II. Modification by adriamycin. International Journal of Immunopharmacology. 6: 521-7. PMID 6238914 DOI: 10.1016/0192-0561(84)90091-2 |
0.376 |
|
1984 |
Ryoyama K, Ryoyama C, Ehrke MJ, Mihich E. Induction of suppressor T cells in culture--I. Cell-cell interactions. International Journal of Immunopharmacology. 6: 509-20. PMID 6238913 DOI: 10.1016/0192-0561(84)90090-0 |
0.366 |
|
1983 |
Ehrke MJ, Tomazic V, Ryoyama K, Cohen SA, Mihich E. Adriamycin induced immunomodulation: dependence upon time of administration. International Journal of Immunopharmacology. 5: 43-8. PMID 6404846 DOI: 10.1016/0192-0561(83)90070-X |
0.359 |
|
1983 |
Schlaefli E, Ehrke MJ, Mihich E. The effects of dichloro-trans-dihydroxy-bis-isopropyl-amine-platinum IV on the primary cell-mediated cytotoxic response. Immunopharmacology. 6: 107-22. PMID 6224759 DOI: 10.1016/0162-3109(83)90004-8 |
0.397 |
|
1983 |
Ehrke MJ, Reino JM, Eppolito C, Mihich E. The effect of PS-K, a protein bound polysaccharide, on immune responses against allogeneic antigens. International Journal of Immunopharmacology. 5: 35-42. PMID 6220984 DOI: 10.1016/0192-0561(83)90069-3 |
0.332 |
|
1983 |
Leung KH, Ehrke MJ, Mihich E. Modification by biological products of the generation of suppressor cells in culture. Immunopharmacology. 5: 221-37. PMID 6219969 DOI: 10.1016/0162-3109(83)90029-2 |
0.359 |
|
1982 |
Cohen SA, Ehrke MJ, Ryoyama K, Mihich E. Augmentation of the phagocytic activity of murine spleen cell populations induced by Adriamycin. Immunopharmacology. 5: 75-84. PMID 7129860 DOI: 10.1016/0162-3109(82)90038-8 |
0.357 |
|
1982 |
Leung KH, Ehrke MJ, Bercsenyi K, Mihich E. Human prealbumin fraction: effects on cell-mediated immunity and tumor rejection. Immunopharmacology. 4: 55-67. PMID 7061225 DOI: 10.1016/0162-3109(82)90025-X |
0.397 |
|
1982 |
Bogyo D, Ehrke MJ, Mihich E. Reversal by citrovorum factor of methotrexate-induced suppression of cell-mediated and humoral immune response in mouse model systems. Biochemical Pharmacology. 31: 1387-92. PMID 6980004 DOI: 10.1016/0006-2952(82)90033-8 |
0.334 |
|
1982 |
Leung KH, Mihich E. Effects of prostaglandins on the development of cell-mediated immunity in culture and on the cytolytic activity of in vivo-generated effector cells. International Journal of Immunopharmacology. 4: 205-17. PMID 6809648 DOI: 10.1016/0192-0561(82)90050-9 |
0.376 |
|
1982 |
Leung KH, Ehrke MJ, Mihich E. Modulation of the development of cell-mediated immunity: possible role of the products of the cyclo-oxygenase and the lipoxygenase pathways of arachidonic acid metabolism. International Journal of Immunopharmacology. 4: 195-204. PMID 6809647 DOI: 10.1016/0192-0561(82)90049-2 |
0.312 |
|
1982 |
Ryoyama K, Mace K, Ehrke MJ, Mihich E. The differential sensitivity of T cell immune functions to vincristine and vinblastine. International Journal of Immunopharmacology. 4: 187-93. PMID 6213573 DOI: 10.1016/0192-0561(82)90048-0 |
0.389 |
|
1980 |
Leung KH, Mihich E. Prostaglandin modulation of development of cell-mediated immunity in culture. Nature. 288: 597-600. PMID 7003398 DOI: 10.1038/288597A0 |
0.34 |
|
1980 |
Leung KH, Mihich E. Modulation of cell-mediated immunity by inhibitors of prostaglandin syntheses International Journal of Immunopharmacology. 2: 244-245. DOI: 10.1016/0192-0561(80)90221-0 |
0.313 |
|
1977 |
Bennett J, Ehrke J, Dave C, Mihich E. Selective effects of methylglyoxal-bis-(guanylhydrazone) on the development of antibody-forming cells in mice. Biochemical Pharmacology. 26: 723-8. PMID 856204 DOI: 10.1016/0006-2952(77)90215-5 |
0.363 |
|
1977 |
Medzihradsky J, Ehrke J, Mihich E. Time limitations in the reversal by citrovorum factor of methotrexate-induced immunosuppression in mice. Biochemical Pharmacology. 26: 203-206. PMID 300243 DOI: 10.1016/0006-2952(77)90303-3 |
0.335 |
|
1975 |
Orsini FR, Mihich E. Bone marrow determination of complement dependent and complement independent cellular cytotoxicity Cellular Immunology. 18: 424-434. PMID 1095218 DOI: 10.1016/0008-8749(75)90070-2 |
0.307 |
|
1973 |
Mawas C, Carey T, Mihich E. Study of the immune responses to nucleated cells. I. In vitro functional evaluation of the immune effectors responsible for complement-dependent cellular cytotoxicity Cellular Immunology. 6: 243-260. PMID 4540377 DOI: 10.1016/0008-8749(73)90025-7 |
0.348 |
|
Show low-probability matches. |